Stoney did you see the Kamikaze Drone coverage on all the MSM by https://www.avinc.com/ Stock has held up well.
How does that help my $150 price entry Average down in a Bear Market, I liked it in the high $80s and low $90s when Van was recommending it during Lockdown. Michael Reeves used a goldfish to bet against /r/WallStreetBets... and won lmao.
O-I Glass price target raised to $15 from $14 at Barclays 05:36 OI Barclays analyst Michael Leithead raised the firm's price target on O-I Glass to $15 from $14 and keeps an Equal Weight rating on the shares. The Q1 results in U.S. chemicals "have broadly been solid with cautious optimism from most companies, despite an uncertain macro backdrop," Leithead tells investors in a research note. Almost all the fiscal year guides have been raised less than Q1 outperformance, however, says the analyst. However, he does not think this portends a second half of 2022 slowdown; rather, he think this "creates some cushion" in current fiscal year estimates. OI- IS A BARE ESSENTIAL <--------
GBA GUMMY TIME-! Innoviz Technologies selected by large vehicle manufacturer 07:06 INVZ Innoviz Technologies announced that one of the largest vehicle manufacturers in the world has selected Innoviz to become its direct LiDAR supplier across multiple brands. The selection, which is Innoviz's third major design win, follows more than two years of extensive diligence and qualification, and will increase Innoviz's forward-looking order book by $4B-$6.6B.<-------
AbbVie selloff Friday 'very much overdone,' says JPMorgan 07:20 ABBV JPMorgan analyst Chris… ABBV is a BARE ESENTIAL
Piper sees 'outright misinformation' on Biohaven, says buy shares 06:36 BHVN, ABBV In a research note titled "Everybody Just Take a Chill Pill," Piper Sandler analyst Christopher Raymond keeps an Overweight rating on Biohaven Pharmaceutical with a $170 price target. The recent pullback in the shares is driven by a combination of "misdirected" Nurtec concerns over AbbVie's Ubrelvy/Qulipta print and "outright misinformation" from a short report that mischaracterized a number of Biohaven's accounting practices, Raymond tells investors in a research note. The analyst thinks investors would do well to buy the stock on weakness. The analyst sees nothing to change his conviction that Nurtec is on its way to becoming a $4B franchise.
When you invest for people who are scared you must take a methodical approach. How much of $100K should I employ today? Van do you have any ideas?
Global Payments reports Q1 adjusted EPS $2.07, consensus $2.04 06:55 GPN Reports Q1 GAAP revenue $2.16B, consensus $1.96B. Reports adjusted revenue $1.95B. Show Related Items >> I have owned this name on and off so many times I actually have to call in today to see if I still own it I believe I do not. HOWEVER this is always a stock that I sold because someone else in the sector was F ing up (PYPL)
Looks like you have enough already. If tech starts up and you want another tech stock, use TWLO or UPST.